Page last updated: 2024-12-06

harmol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

harmol: harmol is oxidized form of alkaloid harmolol; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68094
CHEMBL ID14285
CHEMBL ID486817
CHEBI ID192558
CHEBI ID95347
SCHEMBL ID177685
SCHEMBL ID10024119
MeSH IDM0041458

Synonyms (96)

Synonym
bdbm50047009
1-methyl-9h-beta-carbolin-7-ol (harmalol)
BRD-K01225247-311-03-7
BRD-K01225247-003-02-2
KBIO1_001492
DIVK1C_006548
NCIOPEN2_000349
NCI60_013489
SDCCGMLS-0066699.P001
mls000736795 ,
487-03-6
nsc-72292
harmol
nsc72292
SPECTRUM_000339
tnp00139
NCGC00017250-01
BPBIO1_000600
PRESTWICK3_000612
SPECTRUM5_000853
BSPBIO_002942
PRESTWICK2_000612
9h-pyrido[3,4-b]indol-7-ol, 1-methyl-
1-methyl-9h-beta-carbolin-7-ol
1-methyl-9h-pyrido[3,4-b]indol-7-ol
AB00053725
smr000528328
NCGC00142521-01
KBIO3_002442
KBIO2_005955
KBIOSS_000819
KBIOGR_000847
KBIO2_000819
KBIO2_003387
SPECTRUM3_001531
SPECTRUM2_000504
SPECPLUS_000452
SPBIO_000427
SPECTRUM4_000214
PRESTWICK1_000612
SPBIO_002763
PRESTWICK0_000612
BSPBIO_000544
H-1300
1-methyl-9h-pyrido(3,4-b)indol-7-ol
CHEMBL14285 ,
1-methyl-2,9-dihydropyrido[3,4-b]indol-7-one
7-hydroxyl-1-methyl-beta-carboline
1-methyl-7-hydroxy-beta-carboline
CHEBI:192558
1-methylbeta-carbolin-7-ol
unii-7pq075mca6
7pq075mca6 ,
einecs 207-645-9
9h-pyrido(3,4-b)indol-7-ol, 1-methyl-
nsc 72292
AKOS006227799
CHEMBL486817
NCGC00017250-02
FT-0603420
CCG-214814
SCHEMBL177685
H1360
SCHEMBL10024119
1-methyl-9h-?-carbolin-7-ol
A1-00784
bdbm55885
1-methyl-2,9-dihydro-beta-carbolin-7-one
cid_68094
.beta.-carboline, 7-hydroxy-1-methyl-
1-methyl-9h-beta-carbolin-7-ol #
7-hydroxy-1-methyl-9h-pyrido[3,4-b]indole
mfcd00834164
methylpyridoindolol
SR-01000761196-4
sr-01000761196
CHEBI:95347
1-methyl-9h-pyrido[3,4-b]indol-7-ol, 9ci
7-hydroxyharman
9h-pyrido(3,4-b)indol-7-ol, 1-methyl- (8ci)(9ci)
beta 7-hydroxy-1-methyl--carboline
DTXSID10876697
bdbm50498226
Q15411005
STL565076
T72515
1-methyl-2,9-dihydro-7h-pyrido[3,4-b]indol-7-one
DTXSID10960989
WS-02001
cid 5280952
CS-0030686
HY-107811
1-methyl-9h-pyrido[3,4-b]indol-7-ol monohydrochloride dihydrate
nsc 72292 monohydrochloride dihydrate
1-methyl-9~{h}-pyrido[3,4-b]indol-7-ol
HFI ,

Research Excerpts

Treatment

Harmol treatment reduced phosphorylation of Akt, mammalian target of rapamycin (mTOR) and downstream targets p70-ribosomal protein S6 kinase and 4E-binding protein 1. Treatment with harmol induces a transient mitochondrial depolarization, a strong mitophagy response and the AMPK compensatory pathway.

ExcerptReferenceRelevance
"Harmol treatment reduced phosphorylation of Akt, mammalian target of rapamycin (mTOR) and its downstream targets p70-ribosomal protein S6 kinase and 4E-binding protein 1, resulting in induction of autophagy."( Harmol induces autophagy and subsequent apoptosis in U251MG human glioma cells through the downregulation of survivin.
Abe, A; Kokuba, H, 2013
)
2.55
"Treatment with harmol induces a transient mitochondrial depolarization, a strong mitophagy response, and the AMPK compensatory pathway both in cultured C2C12 myotubes and in male mouse liver, brown adipose tissue and muscle, even though harmol crosses poorly the blood-brain barrier."( Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models.
Ballesteros-Gonzalez, Á; Costa-Machado, LF; Del Pino, I; Duerr, JS; Eisenberg, T; Fabregat-Safont, D; Fernandez-Marcos, PJ; Fornari, T; Galindo, MI; Garcia-Dominguez, E; Gomez, J; Gomez-Cabrera, MC; Herradon, G; Hofer, SJ; Houtkooper, RH; Lopez-Aceituno, JL; Loza, MI; Madeo, F; Magnes, C; McIntyre, RL; Megias, D; Perez, M; Plaza, A; Pozo, OJ; Sierra-Ramirez, A; Tapia-Gonzalez, A; Villanueva-Bermejo, D; Viña, J, 2023
)
1.49

Dosage Studied

The role of Mrp2, Bcrp, and P-glycoprotein in the biliary excretion of acetaminophen sulfate (AS) and glucuronide (AG) was studied in Abcc2, Abcg2, and Abcb1a. At the higher dosage of harmol, phorone reduced the bility excretion harmol sulfate while increasing the excrement of harmol glucuronide.

ExcerptRelevanceReference
" At the higher dosage of harmol, phorone reduced the biliary excretion of harmol sulfate while increasing the biliary excretion of harmol glucuronide."( Effect of glutathione depletion on sulfate activation and sulfate ester formation in rats.
Gregus, Z; Howell, S; Klaassen, CD; White, C, 1988
)
0.58
" beta CCE and beta CCtB produced dose-related, parallel shifts in the dose-response curve for the discriminative effects of diazepam, but the magnitude of the shifts was limited: the two highest doses of beta CCE and beta CCtB produced shifts that were not significantly different in magnitude."( Beta-carbolines as antagonists of the discriminative stimulus effects of diazepam in rats.
Cook, JA; Guzman, F; Hagen, TJ; Shannon, HE, 1988
)
0.27
"The role of Mrp2, Bcrp, and P-glycoprotein in the biliary excretion of acetaminophen sulfate (AS) and glucuronide (AG), 4-methylumbelliferyl sulfate (4MUS) and glucuronide (4MUG), and harmol sulfate (HS) and glucuronide (HG) was studied in Abcc2(-/-), Abcg2(-/-), and Abcb1a(-/-)/Abcb1b(-/-) mouse livers perfused with the respective parent compounds using a cassette dosing approach."( The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.
Brouwer, KL; Kalvass, JC; Nezasa, K; Patel, NJ; Raub, TJ; Tian, X; Zamek-Gliszczynski, MJ, 2006
)
0.73
" In the present study, the involvement in this process of Mrp3 and Mrp4, two basolateral efflux transporters, was evaluated by analyzing the hepatic basolateral excretion of the glucuronide and sulfate metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3(-/-) and Abcc4(-/-) mice using a cassette dosing approach."( Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice.
Belinsky, MG; Bridges, AS; Brouwer, KL; Kruh, GD; Lee, K; Nezasa, K; Tian, X; Zamek-Gliszczynski, MJ, 2006
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
harmala alkaloidAny member of a class of naturally occurring alkaloids based on a 1-methyl-9H-beta-carboline skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
beta-carboline biosynthesis09
beta-carboline biosynthesis08

Protein Targets (55)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.83260.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.83260.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency28.18385.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency32.46480.100020.879379.4328AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency5.80240.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency18.05700.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
67.9K proteinVaccinia virusPotency11.22020.00018.4406100.0000AID720579
glucocerebrosidaseHomo sapiens (human)Potency19.95260.01268.156944.6684AID2101
alpha-galactosidaseHomo sapiens (human)Potency42.23954.466818.391635.4813AID2107
IDH1Homo sapiens (human)Potency8.19950.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency15.84890.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency25.11890.316212.443531.6228AID902
cytochrome P450 2C19 precursorHomo sapiens (human)Potency25.11890.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency15.84890.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency8.19950.00419.984825.9290AID504444
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency78.43520.794321.275750.1187AID624246; AID651804
DNA polymerase betaHomo sapiens (human)Potency28.18380.022421.010289.1251AID485314
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency8.91250.010323.856763.0957AID2662
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.00790.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Glycoprotein hormones alpha chainHomo sapiens (human)Potency1.58494.46688.344810.0000AID624291
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
neutrophil cytosol factor 1Homo sapiens (human)IC50 (µMol)36.50000.39006.544129.1200AID1275
rac GTPase-activating protein 1 isoform aHomo sapiens (human)IC50 (µMol)44.91007.390057.8904301.2400AID624330
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)2,000.00000.05373.075710.0000AID638472
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)IC50 (µMol)0.09000.00310.71409.0120AID1420021
Serine/threonine-protein kinase haspinHomo sapiens (human)IC50 (µMol)0.77000.00200.19070.7700AID655305
Dual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)IC50 (µMol)1.50000.01400.97443.0000AID653129
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA repair and recombination protein RAD54-like isoform 1Homo sapiens (human)AC5023.89000.814019.311978.9500AID651657
dual specificity tyrosine-phosphorylation-regulated kinase 1ARattus norvegicus (Norway rat)AC500.29800.00564.693226.6940AID588345
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
chromatin remodelingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IIDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nervous system developmentDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
circadian rhythmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of microtubule polymerizationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of RNA splicingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
amyloid-beta formationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-serine autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-tyrosine autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of mRNA splicing, via spliceosomeDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of DNA methylation-dependent heterochromatin formationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of protein deacetylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase haspinHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase haspinHomo sapiens (human)
mitotic sister chromatid cohesionSerine/threonine-protein kinase haspinHomo sapiens (human)
mitotic spindle assembly checkpoint signalingSerine/threonine-protein kinase haspinHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase haspinHomo sapiens (human)
protein localization to chromosome, centromeric regionSerine/threonine-protein kinase haspinHomo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase haspinHomo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
DNA damage responseDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
smoothened signaling pathwayDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
positive regulation of glycogen biosynthetic processDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
identical protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
tau protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
tau-protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
histone H3T45 kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
transcription coactivator activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase haspinHomo sapiens (human)
protein bindingSerine/threonine-protein kinase haspinHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase haspinHomo sapiens (human)
histone H3T3 kinase activitySerine/threonine-protein kinase haspinHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase haspinHomo sapiens (human)
magnesium ion bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
manganese ion bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoskeletonDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nuclear speckDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
axonDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
dendriteDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
ribonucleoprotein complexDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleusSerine/threonine-protein kinase haspinHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase haspinHomo sapiens (human)
chromosomeSerine/threonine-protein kinase haspinHomo sapiens (human)
centrosomeSerine/threonine-protein kinase haspinHomo sapiens (human)
spindleSerine/threonine-protein kinase haspinHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase haspinHomo sapiens (human)
nucleusSerine/threonine-protein kinase haspinHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytosolDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ubiquitin ligase complexDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ribonucleoprotein complexDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoskeletonDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID95653In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID42569In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID655305Inhibition of human recombinant N-terminal MBP-tagged haspin kinase expressed in Escherichia coli DE3 after 10 mins by TR-FRET assay2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
AID213899In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line.1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID1226058Inhibition of L3 larval stage of Onchocerca volvulus chitinase using 4-methylumbelliferyl-N-N'-N''-beta-chitotrioside as substrate assessed as release of 4-methylumbelliferone measured for 10 mins by fluorescence assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.
AID2964In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID1226060Inhibition of Entamoeba histolytica chitinase using 4-methylumbelliferyl-N-N'-N''-beta-chitotrioside as substrate assessed as release of 4-methylumbelliferone at 10 uM measured for 10 mins by fluorescence assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.
AID638472Inhibition of IDO12012Bioorganic & medicinal chemistry, Feb-01, Volume: 20, Issue:3
Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen.
AID55536Percentage inhibition against cyclin dependent kinase 5 (CDK 5) at a concentration of 50 uM2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Beta-carbolines as specific inhibitors of cyclin-dependent kinases.
AID1226061Inhibition of Brugia malayi chitinase using 4-methylumbelliferyl-N-N'-N''-beta-chitotrioside as substrate assessed as release of 4-methylumbelliferone at 10 uM measured for 10 mins by fluorescence assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.
AID1226063Antionchocerciasis activity against L3 larval stage of Onchocerca volvulus assessed as inhibition of parasite molting at 10 uM treated for 24 hrs prior to complete medium and PBMC addition measured after 6 days by inverted microscopic analysis2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.
AID357033Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication2001Journal of natural products, Jul, Volume: 64, Issue:7
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives.
AID8467In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID55535Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Beta-carbolines as specific inhibitors of cyclin-dependent kinases.
AID125789Inhibitory effect on Bufuralol 1'-hydroxylation by human liver microsomes (Ki = apparent inhibition constant)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID357034Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV12001Journal of natural products, Jul, Volume: 64, Issue:7
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives.
AID357032Cytotoxicity against human H9 cells2001Journal of natural products, Jul, Volume: 64, Issue:7
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives.
AID653129Inhibition of DYRK22012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
AID1226062Mitochondrial uncoupling activity in HEK293T/17 cells at 50 uM after 30 mins by TMRE staining-based fluorescence assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.
AID103712In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line.1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID1882205Antifungal activity against Alternaria solani relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Natural and synthetic β-carboline as a privileged antifungal scaffolds.
AID1882206Antifungal activity against Bipolaris maydis relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Natural and synthetic β-carboline as a privileged antifungal scaffolds.
AID1420021Inhibition of human recombinant full length GST-tagged DYRK1A expressed in baculovirus expression system assessed as decrease in tau phosphorylation at S396 preincubated for 10 mins followed by tau addition by Western blot analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (80)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (43.75)18.7374
1990's16 (20.00)18.2507
2000's9 (11.25)29.6817
2010's15 (18.75)24.3611
2020's5 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.29 (24.57)
Research Supply Index4.44 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.20%)5.53%
Reviews2 (2.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other80 (96.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]